DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg
A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Doravirine/Islatravir (100 mg/0.25 mg) in Pediatric Participants With HIV-1 Infection Who Are Virologically Suppressed or Treatment-Naïve, Are Less Than 18 Years of Age, and Weigh Greater Than or Equal to 35 kg
This is a phase 2 study of the pharmacokinetics, safety, and efficacy of oral doravirine/islatravir (100 mg/0.25 mg) [MK-8591A] in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection who are virologically suppressed or treatment-naive.
The Base Study will last from Day 1 to Week 96. At Week 96, participants will be given the option to participate in an optional Study Extension and receive DOR/ISL until Week 240 or until it becomes commercially accessible, whichever is first.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Toll Free Number
- 전화번호: 1-888-577-8839
- 이메일: Trialsites@merck.com
연구 장소
-
-
Florida
-
Tampa, Florida, 미국, 33612
- University of South Florida ( Site 1505)
-
연락하다:
- Study Coordinator
- 전화번호: 813-821-8039
-
-
New York
-
The Bronx, New York, 미국, 10467
- The Children's Hospital at Montefiore ( Site 1507)
-
연락하다:
- Study Coordinator
- 전화번호: 718-741-2497
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Pediatric participant with HIV-1 <18 years of age
- Body weight ≥35 kg
- Is TN (HIV-1 positive with plasma HIV-1 RNA ≥500 copies/mL) or VS (HIV-1 positive at screening with plasma HIV-1 RNA <50 copies/mL AND has received stable, continuous 2- or 3-drug antiretroviral therapy (ART) for ≥3 months prior to providing informed consent)
Exclusion Criteria:
- HIV-2 infection
- Hypsensitivity/contraindication to any components of study medication or as determined by the investigator
- Has an active diagnosis of hepatitis due to any cause
- history of malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi's sarcoma
- Has a history or current evidence of any condition (including active tuberculosis infection, COVID-19, or other infections), therapy, laboratory abnormality, or other circumstance (including drug or alcohol use or dependence) that might, in the opinion of the investigator, confound the results of the study
- Is taking or is anticipated to require systemic immunosuppressive therapy, immune modulators, or any prohibited therapies
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: DOR/ISL
Participants receive DOR/ISL 100 mg/0.25 mg once daily (qd) for 96 weeks. Participants will have the option to participate in the Study Extension and receive DOR/ISL until Week 240 or it becomes commercially available, whichever is first. |
DOR/ISL 100 mg/0.25 mg tablet taken by mouth qd
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Area under the plasma conentration-time curve from dosing to 24 hours postdose (AUC0-24) of ISL
기간: At designated timepoints on Day 28
|
The plasma AUC0-24 will be assessed. |
At designated timepoints on Day 28
|
|
Maximum plasma concentration (Cmax) of ISL
기간: At designated timepoints on Day 28
|
The plasma Cmax will be assessed. |
At designated timepoints on Day 28
|
|
Time to maximum plasma concentration (Tmax) of ISL
기간: At designated timepoints on Day 28
|
The plasma Tmax will be assessed. |
At designated timepoints on Day 28
|
|
Apparent plasma terminal half-life (t½) of ISL
기간: At designated timepoints on Day 28
|
The plasma t½ will be assessed. |
At designated timepoints on Day 28
|
|
Apparent clearance (CL/F) of ISL
기간: At designated timepoints on Day 28
|
The CL/F will be assessed. |
At designated timepoints on Day 28
|
|
Volume of distribution (Vz/F) of ISL
기간: At designated timepoints on Day 28
|
The Vz/F will be assessed. |
At designated timepoints on Day 28
|
|
Percentage of participants with ≥1 adverse event (AE) through Week 24
기간: Up to ~24 weeks
|
The percentage of participants with AE(s) will be assessed. |
Up to ~24 weeks
|
|
Percentage of participants discontinuing from study therapy due to AE(s) through Week 24
기간: Up to ~24 weeks
|
The percentage of participants discontinuing from therapy due to AE(s) will be assessed. |
Up to ~24 weeks
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of participants with ≥1 AE through Week 96
기간: Up to 96 weeks
|
The percentage of participants with AE(s) will be assessed. |
Up to 96 weeks
|
|
Percentage of participants discontinuing from study therapy due to AE(s) through Week 96
기간: Up to 96 weeks
|
The percentage of participants with AE(s) will be assessed. |
Up to 96 weeks
|
|
Percentage of virologically-suppressed (VS) participants with Human Immunodeficiency Virus Type 1 (HIV-1) ribonucleic acid (RNA) ≥50 copies/mL
기간: Weeks 24, 48, and 96
|
The percentage of VS participants with HIV-1 RNA ≥50 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Percentage of VS participants with HIV-1 RNA <50 copies/mL
기간: Weeks 24, 48, and 96
|
The percentage of VS participants with HIV-1 RNA <50 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Percentage of VS participants with HIV-1 RNA <200 copies/mL
기간: Weeks 24, 48, and 96
|
The percentage of VS participants with HIV-1 RNA <200 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Percentage of treatment-naive (TN) participants with HIV-1 RNA <50 copies/mL
기간: Weeks 24, 48, and 96
|
The percentage of TN participants with HIV-1 RNA <50 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Percentage of TN participants with HIV-1 RNA <200 copies/mL
기간: Weeks 24, 48, and 96
|
The percentage of TN participants with HIV-1 RNA <200 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Change from baseline in CD4+ T-cell counts in VS and TN participants
기간: Weeks 24, 48, and 96
|
The change from baseline in CD4+ T-cell counts will be assessed in VS and TN participants. |
Weeks 24, 48, and 96
|
|
Percentage of participants with viral drug resistance to DOR or ISL
기간: Weeks 24, 48, 96, and 144
|
The percentage of participants with viral resistance-associated substitutions will be assessed during Weeks 24, 48, 96, and 144. |
Weeks 24, 48, 96, and 144
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 8591A-063
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .